|
|
| Line 12: |
Line 12: |
| | | | |
| | <nav id="main-nav"> | | <nav id="main-nav"> |
| − | <div class="vlogo"><img src="https://2017.igem.org/wiki/skins/Igem/images/IGEM_white_letters.png" alt="" /></div> | + | <div class="vlogo"> |
| | + | <img src="https://2017.igem.org/wiki/skins/Igem/images/IGEM_white_letters.png" alt="" /> |
| | + | </div> |
| | <ul id="options" class="clearfix"> | | <ul id="options" class="clearfix"> |
| | <li> | | <li> |
| Line 43: |
Line 45: |
| | <a href="https://2017.igem.org/Team:ASTWS-China/Experiments">Experiment</a> | | <a href="https://2017.igem.org/Team:ASTWS-China/Experiments">Experiment</a> |
| | </li> | | </li> |
| − | <li>
| |
| − | <a href="https://2017.igem.org/Team:ASTWS-China/Notebook">Notebook</a>
| |
| − | </li>
| |
| − |
| |
| | <li> | | <li> |
| | <a href="https://2017.igem.org/Team:ASTWS-China/InterLab">InterLab</a> | | <a href="https://2017.igem.org/Team:ASTWS-China/InterLab">InterLab</a> |
| Line 140: |
Line 138: |
| | <article class="element clearfix col3-3 home auto"> | | <article class="element clearfix col3-3 home auto"> |
| | <div class="boxed"> | | <div class="boxed"> |
| − | <h2 class="header">COMMON PAGE</h2> | + | <h2 class="header">Design</h2> |
| | <p> | | <p> |
| − | Our idea of project comes from Hybridoma technology. We found some disadvantage about the old technology. In order to improve this technology, we started this project. We also want to know how most of people thinks about Hybridoma technology and our new approach. So we make a questioner to collect others view about our project. | + | Our project can be divided into four parts. In our team prepared several recombinants proteins as antigens for immunization, and finally separated the B cells from the rabbits that immunized with antigens. In part II, we screened several outer membrane proteins and chose two of the best as donor proteins used in surface display. Then we co-expressed antigen peptides and affinity tags by fusing with these two donor proteins respectively in part III. Through the work of part II and part III, we successfully made the E.coli strains, which we named it ‘smart E.coli’. And in part IV, we did some tests and verifying our project using two models and a real binding experiment. |
| | + | </p> |
| | + | <p> <b>Illustration of this project</b> |
| | </p> | | </p> |
| | <div class="images"> | | <div class="images"> |
| − | <img src="https://static.igem.org/mediawiki/2017/e/e8/T-ASTWS-China-00001.jpeg" alt="" /> | + | <img src="https://static.igem.org/mediawiki/2017/1/12/T-ASTWS-China-p0001.png" alt="" /> |
| | </div> | | </div> |
| | <p> | | <p> |
| − | To know the opinion from normal people, we started a questionnaire on WeChat. | + | Our ‘Smart E.coli’ can also be applied to many aspects with enormous value just by making some little modifications, such as vaccine producing and immune T-cells or tumor cells separations. |
| | </p> | | </p> |
| | + | <p> <b>Illustration of different fields that our smart E.coli can be applied</b> |
| | + | </p> |
| | + | <div class="images"> |
| | + | <img src="https://static.igem.org/mediawiki/2017/4/4a/T-ASTWS-China-p0002.png" alt="" /> |
| | + | </div> |
| | + | |
| | </div> | | </div> |
| | </article> | | </article> |
